Lapatinib increases motility of triple-negative breast cancer cells by decreasing miRNA-7 and inducing Raf-1/MAPK-dependent interleukin-6

Lapatinib, a dual epidermal growth factor receptor (EGFR) and HER2 tyrosine kinase inhibitor (TKI), has been approved for HER2-positive breast cancer patients. Nevertheless, its inhibitory effect on EGFR did not deliver clinical benefits for triple-negative breast cancer (TNBC) patients even EGFR ov...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsiao, Yu-Chun, Yeh, Ming-Hsin, Chen, Yun-Ju, Liu, Ju-Fang, Tang, Chih-Hsin, Huang, Wei-Chien
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741977/
https://www.ncbi.nlm.nih.gov/pubmed/26513016

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741977/
https://www.ncbi.nlm.nih.gov/pubmed/26513016

Ejemplares similares